-
Alcon Experience Academy serves
as umbrella for industry-leading training and educational resources
for all eye care professionals
-
New website houses a robust
library of more than 500 videos, including webcasts and
personalized curricula
-
Trainings offer online and
hands-on experiential learning opportunities at Alcon Experience
Centers around the globe
FORT WORTH, Texas, September 17,
2018 - Alcon, the global leader in eye
care and a division of Novartis, is expanding its extensive, global
support of eye care professionals through the unveiling of the
Alcon Experience Academy. The robust program offers face-to-face
training and online educational resources by leading specialists
from around the world to provide the best patient care possible. As
part of this effort, Alcon is launching a new online portal today,
AlconExperienceAcademy.com, which houses a growing library of
educational materials for healthcare practitioners who engage with
the eye, including eye care professionals, nurses, technicians and
students.
"The Alcon Experience Academy underscores our
dedication to the continuous education of the eye health community
by offering opportunities to discover the latest advancements in
ophthalmic technology at global Alcon Experience Centers, or within
their own practices," said David Endicott, CEO, Alcon. "Through our
industry-leading educational resources, we are fully committed to
providing best-in-class training to help shape the future of eye
care and to provide opportunities for the best-possible patient
outcomes."
The new website includes a robust library of more
than 500 training videos, with additional content added regularly
to an easy-to-navigate home screen. It will also feature webcasts
developed by leading eye care specialists from around the world,
along with personalized videos and curricula across several disease
states and focus areas. The website materials primarily focus on
real-world surgical case studies using the latest innovations in
eye care. Resources specific to optometry are due to be released
early next year.
Training is a hallmark of Alcon's commitment to
eye care professionals, with thousands receiving hands-on
experience every year on the latest advancements in ophthalmology
and optometry. Through state-of-the art Alcon Experience Centers,
along with virtual reality experiences and the new
AlconExperienceAcademy.com website, Alcon is making immersive
training and education accessible at the convenience of eye care
professionals around the world.
"Alcon has built an extraordinary educational
resource with detailed information about surgical techniques
relevant to both novice and advanced surgeons," said Dr. Steve
Charles, Charles Retina Institute, Germantown, Tenn. "The content
is comprehensive, addressing the needs of retina, cataract,
refractive and glaucoma surgeons as well as their team members. The
site is user-friendly and provides a streamlined experience to
support my team in providing the best patient care possible."
The Alcon Experience Academy builds upon Alcon's
industry leadership and long-standing commitment to contributing to
the worldwide body of knowledge and development of innovative tools
in an effort to eradicate eye diseases. Alcon offers six Alcon
Experience Centers around the globe, along with 26 training centers
and 42 wet labs, providing eye care professionals with
state-of-the-art, comprehensive eye health education, hands-on
experiential learning opportunities and cutting-edge virtual
reality technology for an immersive training experience. Alcon
Experience Centers can be found in the United States (Fort Worth,
Texas), Spain (Barcelona), Japan (Tokyo and Osaka), Australia
(Sydney), Colombia (Bogotá), and soon to be in Brazil (São Paulo)
and China (Beijing).
About Alcon Experience
Academy
The Alcon Experience Academy is the umbrella for Alcon's
industry-leading training for eye care professionals, supporting
staff, residents and students - whether in person, online or
through other hands-on experiential learning opportunities. The
Alcon Experience Academy offers thousands of courses every year,
including immersive virtual reality training and education courses,
online and at Alcon Experience Centers worldwide. The Alcon
Experience Academy website provides training and education
resources on disease states, as well as the latest advancements in
techniques and approaches for the safe and effective use of Alcon
technology. For more information and to register, please visit
AlconExperienceAcademy.com.
Disclaimer
This press release contains forward-looking statements within the
meaning of the United States Private Securities Litigation Reform
Act of 1995. Forward-looking statements can generally be identified
by words such as "potential," "can," "will," "plan," "expect,"
"anticipate," "look forward," "believe," "committed,"
"investigational," "pipeline," "launch," or similar terms, or by
express or implied discussions regarding potential marketing
approvals, new indications or labeling for the investigational or
approved products described in this press release, or regarding
potential future revenues from such products. You should not place
undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future
events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that the
investigational or approved products described in this press
release will be submitted or approved for sale or for any
additional indications or labeling in any market, or at any
particular time. Nor can there be any guarantee that such products
will be commercially successful in the future. In particular, our
expectations regarding such products could be affected by, among
other things, the uncertainties inherent in research and
development, including clinical trial results and additional
analysis of existing clinical data; regulatory actions or delays or
government regulation generally; global trends toward health care
cost containment, including government, payor and general public
pricing and reimbursement pressures; our ability to obtain or
maintain proprietary intellectual property protection; the
particular prescribing preferences of physicians and patients;
general political and economic conditions; safety, quality or
manufacturing issues; potential or actual data security and data
privacy breaches, or disruptions of our information technology
systems, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange
Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press
release as a result of new information, future events or
otherwise.
About Alcon
Alcon is the global leader in eye care. As a division of Novartis,
we offer the broadest portfolio of products to enhance sight and
improve people's lives. Our products touch the lives of more than
260 million people each year living with conditions like cataracts,
glaucoma, retinal diseases and refractive errors, and there are
millions more who are waiting for solutions to meet their eye care
needs. Our purpose is reimagining eye care, and we do this through
innovative products, partnerships with eye care professionals and
programs that enhance access to quality eye care. Learn more at
www.alcon.com.
Alcon is on Facebook. Like us at
www.facebook.com/AlconEyeCare.
About Novartis
Novartis is reimagining medicine to improve and extend people's
lives. As a leading global medicines company, we use innovative
science and digital technologies to create transformative
treatments in areas of great medical need. In our quest to find new
medicines, we consistently rank among the world's top companies
investing in research and development. Novartis products reach
nearly 1 billion people globally and we are finding innovative ways
to expand access to our latest treatments. About 125 000 people of
more than 140 nationalities work at Novartis around the world. Find
out more at www.novartis.com.
Novartis is on Twitter. Sign up to follow
@Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit
www.novartis.com/news/media-library
For questions about the site or required registration, please
contact media.relations@novartis.com
# # #
Novartis Media
Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com
Eric
Althoff
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com |
Wes
Warnock
Alcon Global Communications
+1 817 615 2501 (direct)
+1 210 240 4998 (mobile)
wes.warnock@alcon.com |
Novartis Investor
Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com
Central |
|
North
America |
|
Samir
Shah |
+41 61
324 7944 |
Richard
Pulik |
+1 212
830 2448 |
Pierre-Michel Bringer |
+41 61
324 1065 |
Cory
Twining |
+1 212
830 2417 |
Thomas
Hungerbuehler |
+41 61
324 8425 |
|
|
Isabella
Zinck |
+41 61
324 7188 |
|
|
Media release (PDF)